Spyre Therapeutics (SYRE) Cash & Equivalents (2015 - 2026)

Spyre Therapeutics' Cash & Equivalents history runs 12 years deep, the most recent figure standing at $95.4 million for Q1 2026.

• Quarterly Cash & Equivalents rose 96.83% year-over-year to $95.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95.4 million (up 96.83% YoY) and the FY2025 annual result came in at $85.7 million, down 2.29% from the prior year.
• Cash & Equivalents was $95.4 million for Q1 2026 at Spyre Therapeutics, up from $85.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $235.4 million in Q2 2023 and bottomed at $14.6 million in Q1 2022.
• A 5-year average of $87.2 million and a median of $71.6 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 81.76% — and 2024, when it surged 545.67%.
• Spyre Therapeutics' Cash & Equivalents stood at $34.9 million in 2022, then jumped by 441.82% to $188.9 million in 2023, then slumped by 53.55% to $87.7 million in 2024, then decreased by 2.29% to $85.7 million in 2025, then advanced by 11.35% to $95.4 million in 2026.
• Business Quant data shows SYRE's Cash & Equivalents at $95.4 million in Q1 2026, $85.7 million in Q4 2025, and $64.9 million in Q3 2025.